SAM
EW icon

Strategic Asset Management’s Edwards Lifesciences EW Stock Holding History

Strategic Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$0 Hold
3
– – ﹤0.01% 586
2022
Q2 		$0 Hold
3
– – ﹤0.01% 614
2022
Q1 		$0 Hold
3
– – ﹤0.01% 533
2021
Q4 		$0 Buy
+3
New +$350 ﹤0.01% 500

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Asset Management's EW Position: Q3 2022 in Review

Strategic Asset Management held its Edwards Lifesciences (EW) position steady in Q3 2022 at 3 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Strategic Asset Management first reported a position in EW in Q4 2021 and has held it in 4 quarters since. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • Strategic Asset Management held 3 shares of Edwards Lifesciences worth $0 as of Q3 2022.
  • Strategic Asset Management left its Edwards Lifesciences share count unchanged in Q3 2022.
  • Edwards Lifesciences made up ﹤0.01% of Strategic Asset Management's portfolio in Q3 2022, its #586 holding.
  • Strategic Asset Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 4 quarters since.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Strategic Asset Management's 13F filing for Q3 2022, filed 1 Nov 2022.